Nli International Trimmed By $300,150 Its Kansas City Southern (KSU) Position; Inflarx N.V. (IFRX) SI Increased By 31.95%

Nli International Inc decreased Kansas City Southern (KSU) stake by 5.47% reported in 2019Q1 SEC filing. Nli International Inc sold 2,610 shares as Kansas City Southern (KSU)’s stock rose 1.09%. The Nli International Inc holds 45,100 shares with $5.23M value, down from 47,710 last quarter. Kansas City Southern now has $11.87B valuation. The stock decreased 0.33% or $0.39 during the last trading session, reaching $118.77. About 508,013 shares traded. Kansas City Southern (NYSE:KSU) has risen 6.86% since August 11, 2018 and is uptrending. It has outperformed by 6.86% the S&P500. Some Historical KSU News: 12/03/2018 – KCS’ Mike Upchurch to Address the J.P. Morgan 2018 Aviation, Transportation and Industrials Conference; 08/03/2018 – Kansas City Southern Received Final Resolution From Panel of Mexican Economic Competition Commission; 20/04/2018 – Strong volumes lift Kansas City Southern quarterly profit; 08/03/2018 – KSU:RESOLUTION DISMISSES PRELIM INVESTIGATING AUTHORITY REPORT; 20/04/2018 – Kansas City Southern 1Q Rev $638.6M; 27/04/2018 – Kansas City Southern Joins Blockchain in Transport Alliance; 08/03/2018 – Kansas City Southern: Final Resolution Dismisses Preliminary Report Issued by Investigating Authority of COFECE; 07/05/2018 – KCS’ Mike Upchurch to Address the Bank of America Merrill Lynch 2018 Transportation Conference; 30/05/2018 – Kansas City Southern Presenting at UBS Conference Jun 13; 20/04/2018 – Kansas City Southern Volume Rises More Than Triple Average

Inflarx N.V. (NASDAQ:IFRX) had an increase of 31.95% in short interest. IFRX’s SI was 1.24 million shares in August as released by FINRA. Its up 31.95% from 941,700 shares previously. With 1.56 million avg volume, 1 days are for Inflarx N.V. (NASDAQ:IFRX)’s short sellers to cover IFRX’s short positions. The SI to Inflarx N.V.’s float is 8.17%. The stock decreased 1.45% or $0.04 during the last trading session, reaching $2.71. About 370,260 shares traded. InflaRx N.V. (NASDAQ:IFRX) has declined 90.11% since August 11, 2018 and is downtrending. It has underperformed by 90.11% the S&P500. Some Historical IFRX News: 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $70.36 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Finance.Yahoo.com which released: “Do Insiders Own Shares In InflaRx N.V. (NASDAQ:IFRX)? – Yahoo Finance” on July 19, 2019, also Nasdaq.com with their article: “Health Care Sector Update for 07/19/2019: GLPG,MTP,IFRX – Nasdaq” published on July 19, 2019, Nasdaq.com published: “Health Care Sector Update for 07/19/2019: MDGS,MTP,GLPG,IFRX – Nasdaq” on July 19, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “Health Care Sector Update for 07/19/2019: MTP, ATRA, IFRX, JNJ, ABT, MRK, PFE, AMGN – Nasdaq” published on July 19, 2019 as well as Seekingalpha.com‘s news article titled: “InflaRx up 6% after hours on additional IFX-1 data – Seeking Alpha” with publication date: July 18, 2019.

Investors sentiment increased to 1.06 in Q1 2019. Its up 0.27, from 0.79 in 2018Q4. It increased, as 42 investors sold KSU shares while 157 reduced holdings. 86 funds opened positions while 125 raised stakes. 82.53 million shares or 4.09% less from 86.05 million shares in 2018Q4 were reported. Sei Invs owns 19,122 shares. Fort Lp holds 1,063 shares or 0.02% of its portfolio. Moreover, Conning has 0.01% invested in Kansas City Southern (NYSE:KSU) for 1,750 shares. Connor Clark & Lunn Inv Mngmt Ltd accumulated 9,300 shares. Fjarde Ap, Alabama-based fund reported 40,675 shares. Pittenger Anderson owns 1,000 shares for 0.01% of their portfolio. Moreover, Vigilant Cap Mngmt Lc has 0.02% invested in Kansas City Southern (NYSE:KSU). The Switzerland-based Swiss Financial Bank has invested 0.04% in Kansas City Southern (NYSE:KSU). Stevens Cap Limited Partnership reported 0.05% stake. Paloma Prtn Mgmt accumulated 3,172 shares. Hartford Invest reported 11,039 shares. Oregon Public Employees Retirement Fund, Oregon-based fund reported 10,696 shares. Gemmer Asset Mngmt Limited holds 181 shares or 0.01% of its portfolio. Congress Asset Mngmt Com Ma has invested 0.01% in Kansas City Southern (NYSE:KSU). Zurcher Kantonalbank (Zurich Cantonalbank), Switzerland-based fund reported 25,302 shares.

Nli International Inc increased Sherwin Williams Co (NYSE:SHW) stake by 2,540 shares to 4,210 valued at $1.81 million in 2019Q1. It also upped Marathon Oil Corp (NYSE:MRO) stake by 39,230 shares and now owns 79,150 shares. Elanco Animal Health Inc was raised too.

More notable recent Kansas City Southern (NYSE:KSU) news were published by: Finance.Yahoo.com which released: “Read This Before Buying Kansas City Southern (NYSE:KSU) Shares – Yahoo Finance” on July 20, 2019, also Seekingalpha.com with their article: “Kansas City Southern: No Reason To Buy – Seeking Alpha” published on August 09, 2019, Benzinga.com published: “Kansas City Southern Reports Q2 Earnings Beat – Benzinga” on July 19, 2019. More interesting news about Kansas City Southern (NYSE:KSU) were released by: Seekingalpha.com and their article: “Kansas City Southern Earnings Preview – Seeking Alpha” published on July 15, 2019 as well as Benzinga.com‘s news article titled: “Port Of New Orleans Reopens Following Barry – Benzinga” with publication date: July 15, 2019.

Among 7 analysts covering Kansas City Southern (NYSE:KSU), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Kansas City Southern has $14100 highest and $12100 lowest target. $132.29’s average target is 11.38% above currents $118.77 stock price. Kansas City Southern had 15 analyst reports since February 20, 2019 according to SRatingsIntel. The stock of Kansas City Southern (NYSE:KSU) has “Strong Buy” rating given on Thursday, April 18 by Raymond James. The firm earned “Buy” rating on Friday, February 22 by Loop Capital Markets. The rating was maintained by Citigroup with “Buy” on Thursday, April 4. The rating was maintained by Citigroup with “Buy” on Wednesday, March 6. On Monday, July 22 the stock rating was maintained by Raymond James with “Strong Buy”. On Monday, July 22 the stock rating was maintained by JP Morgan with “Neutral”. The stock of Kansas City Southern (NYSE:KSU) earned “Equal-Weight” rating by Morgan Stanley on Monday, July 22. As per Wednesday, February 20, the company rating was maintained by Cowen & Co. The stock has “Equal-Weight” rating by Barclays Capital on Thursday, April 4.

Kansas City Southern (NYSE:KSU) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *